CSI Market
Sign In | Register

Tauriga Sciences Inc (TAUG) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access TAUG Annual Cash Flow →
Looking at cash flow data from Tauriga Sciences Inc through Dec 31 2020 provides insight into Dec 31 2021's financial flexibility across reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2021)
9 Months 		(Sep 30 2021) (Jun 30 2021) (Mar 31 2021) (Dec 31 2020)
Operating Activities
Income-4.11
Depreciation & amortization0.00
Amortization of Other Assets0.39
Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.01
Increase (Decrease) in Inventories0.21
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation1.07
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Extinguishment Of Debt Gain Loss Net Of Tax-
Convertible Debenture Repayment Premium-
Discontinued Operation Amount Of Adjustment To Prior Period Gain Loss On Disposal Net Of Tax-
Amortization On Loan Discount-
Impairment Of Advances-
Impairment Of Advances To Related Parties-
License Costs-
Note Payable Discount Amortization-
Amortization Of Deferred Charges-
Accretion On Convertible Notes Payable-
Gain Loss On Derivative Instruments Net Pretax-
Impairment Of Patents-
Original Issue Discounts Interest-
Stock Issued During Period Value Other-
Change In Noncontrolling Interest On Cash-
Gain On Settlement Of Operating Activities-
Gain Loss On Sale Of Commodities-
Gain On Settlement-
Debt And Equity Securities Gain Loss-
Gain Loss On Sale Of Trading Securities-
Increase Decrease In Debt Securities Trading2.44
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.02
Increase (Decrease) in Accounts Payable-0.15
Accrued Expense0.14
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.04
Other Working Capital0.00
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.50
Discontinued operations0.00
Net Cash flow from Operating Activities-1.44
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Held-to-maturity Securities0.00
Real Estate Investments0.00
Purchase Of Intangible Assetsdomain Name-
Purchase Of Marketable Securities-
Net Advances To Immunovative Therapies Ltd. For Future Stock Ownership-
Payments Of Deferred Acquisition Costs-
Payment For License-
Payment For Advance To Acquire Business-
Contribution Of Services-
Proceeds From Sale Of Securities-
Purchase Of Digital Currency-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Proceeds from Collection of Loans Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net1.20
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.25
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.45
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Commisions Paid On Sale Of Common Stock-
Commission Paid On Sales Of Common Stock-
Bank Overdraft-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.40
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-1.45
Total Cash Flow-0.04
4 historic quarters locked

Sign in to unlock the full Tauriga Sciences Inc cash flow history.

Sign In Create Free Account

About TAUG Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.